Perseus Proteomics Company Description

Perseus Proteomics Inc., a drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan.

The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products.

Its product pipeline includes PPMX-T001, an anti-hepatocarcinoma antibody; PPMX-T002, an anticancer drug; PPMX-T003, a drug for the treatment of adult T-cell; and PPMX-T004, an antibody drug conjugate.

The company was incorporated in 2001 and is headquartered in Tokyo, Japan.

Perseus Proteomics Inc.

Country	Japan
Founded	2001
Industry	Drug Manufacturers - General
Sector	Healthcare
Employees	25
CEO	Takuya Yokokawa

Contact Details

Address: 30-1 Nihonbashi Hakozakicho Tokyo, 103-0015 Japan
Phone	81 3 6264 8268
Website	ppmx.com

Stock Details

Ticker Symbol	4882
Exchange	Tokyo Stock Exchange
Stock Type	Common Stock
Fiscal Year	April - March
Reporting Currency	JPY
ISIN Number	JP3836800007
SIC Code	2836

Key Executives

Name	Position
Takuya Yokokawa	Chief Executive Officer